Anavex Life Sciences Reports Promising Results in Parkinson’s Disease Dementia Study
Anavex Life Sciences has announced encouraging findings from its 48-week Phase 2 extension study
involving ANAVEX®2-73 (blarcamesine) for patients with Parkinson’s disease
dementia. The clinical-stage biopharmaceutical company reported that the study
met both its primary and secondary objectives, showcasing significant
improvements in patient outcomes.
The study monitored safety, tolerability, and efficacy over a 48-week period. Participants
exhibited better performance in all efficacy endpoints while on ANAVEX®2-73.
These endpoints included the Movement Disorder Society-Unified Parkinson’s
Disease Rating Scale (MDS-UPDRS) and Clinical Global Impression – Improvement
(CGI-I). The results underline the drug’s potential to slow and possibly
reverse the symptoms of Parkinson’s disease dementia.
Dr. Christopher U. Missling, President & CEO of Anavex Life Sciences, highlighted the consistent
improvement in patients’ clinical symptoms during the extension phase. This suggests that
ANAVEX®2-73 could be a groundbreaking treatment for managing Parkinson’s
disease, which remains a significant unmet medical need globally.
Notably, the study’s participants continued their treatment beyond the 48-week period
through the compassionate use Special Access Scheme. This extension underscores
the positive reception and demand for ANAVEX®2-73 among patients.
Anavex is also in partnership with the Michael J. Fox Foundation (MJFF), which awarded the company a research grant
for an imaging-focused clinical trial. This collaboration aims to further
explore the therapeutic potential of ANAVEX®2-73.
With these promising results, Anavex Life Sciences is poised to proceed with a pivotal
trial to validate ANAVEX®2-73’s efficacy in treating Parkinson’s disease. The
company’s ongoing research efforts continue to hold promise for developing
comprehensive treatments for various neurodegenerative and neurodevelopmental disorders.
Go to this page for additional information.
Learn more about Anavex on https://www.bloomberg.com/profile/company/AVXL:US